Skip to main content
NewslettersWatchlist

Crescita Therapeutics Inc(CTX-T)
TSX

Today's Change
Real-Time Last Update
Day Low0.4300
Day High0.4400
Open:0.4400
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Automated Summaries - The Globe and Mail
Closing Bell: Crescita Therapeutics Inc down on Thursday (CTX)
AI-generated - The Globe and Mail
Crescita Therapeutics: Stocks trading at Less Than Cash Value on TSX (CTX)
Baystreet
Stocks in play: Crescita Therapeutics Inc.
Business Wire
Crescita Reports Q4 and Fiscal 2022 Results
Business Wire
Crescita Reports Third Quarter 2022 Results
Business Wire
Crescita Reports Second Quarter 2022 Results
Business Wire
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
Business Wire
Crescita Reports First Quarter 2022 Results
Business Wire
Crescita to Present at Bloom Burton & Co. Healthcare Investor Conference
Business Wire
Crescita Reports Q4 and Fiscal 2021 Results
Baystreet
Stocks in play: Crescita Therapeutics Inc.
Business Wire
Crescita Therapeutics Announces Renewal of Normal Course Issuer Bid
Baystreet
Stocks in play: Crescita Therapeutics Inc.
Business Wire
Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis®
Business Wire
Crescita Reports Third Quarter 2021 Results and Appoints New Board Member
Business Wire
Crescita Announces Exclusive Canadian Distribution Agreement with Obagi Cosmeceuticals LLC
Business Wire
Crescita Acquires Minority Interest in The Best You®
Business Wire
Crescita Therapeutics and STADA Enter 15-Country Exclusive Licensing Agreement for Pliaglis®
Business Wire
Crescita Reports Second Quarter 2021 Results and Provides Corporate Update
Business Wire
Crescita Therapeutics Announces 9-Country Licensing Agreement with Croma Pharma for Pliaglis®
Business Wire
Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
Business Wire
Crescita Reports First Quarter 2021 Results
Business Wire
Crescita Therapeutics to Present at the 2021 Bloom Burton & Co. Healthcare Investor Conference
Business Wire
Crescita Reports Q4 and Fiscal 2020 Results
Canada Newswire
Crescita Reports First Quarter 2020 Results
Canada Newswire
Crescita Therapeutics Announces the Results of its Annual General Meeting of Shareholders
Canada Newswire
Crescita Therapeutics Announces Extension of First Quarter 2020 Filings Due to COVID-19

Profile

Crescita Therapeutics Inc is a Canadian commercial dermatology company with in-house research & development and manufacturing capabilities. The company offers a portfolio of non-prescription skincare products and early to commercial-stage prescription drug products and owns multiple proprietary drug delivery platforms that support the development of patented formulations that can facilitate the delivery of active ingredients into or through the skin. The company has three reportable segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The firm generates its revenue from Commercial Skincare Product Sales in Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.